Phelan-McDermid Syndrome Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Phelan-McDermid Syndrome remains an active clinical development field. One-time and precision therapies are raising the efficacy ceiling, but durability, manufacturing, small-population evidence and long-term safety remain decisive constraints. The PatSnap evidence set used here contains 9 matched trial records and 5 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07593391 | NNZ-2591 | Phase 3; Recruiting | Neuren Pharmaceuticals Ltd. | United States | Long-term safety and tolerability of NNZ-2591 as assessed by the incidence of adverse events across participants (Baseline through Safety Follow-Up (Month 12)); Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of ECG parameters events across participants. (Baseline through Month 12) | 2028-10-29 |
| NCT07281079 | NNZ-2591 | Phase 3; Recruiting | Neuren Pharmaceuticals Ltd. | Canada, United States | Efficacy of NNZ-2591 compared with placebo as measured by the Phelan-McDermid Syndrome Assessment of Change (PMSA-C) overall score. (Week 13); Efficacy of NNZ-2591 compared with placebo as measured by the change from baseline in the Vineland Adaptive Behavior Scales-3, Interview version (Vineland-3) receptive communication subdomain raw score. (Week 13) | 2027-10-31 |
| NCT07119606 | Intervention not normalized | Not Applicable; Not yet recruiting | Assistance Publique des Hôpitaux de Paris SA | France | Better Understanding the Clinical Variability of the Phelan-McDermid Syndrome (18 months) | 2027-03-01 |
| NCT07014020 | RB-001 | Phase 1; Active, not recruiting | Peking University First Hospital | China | To evaluate the safety and tolerability of a single intracerebroventricular injection of RB001 through week 52 (52 weeks) | 2027-05-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- NNZ-2591 in Children and Adolescents With Phelan-McDermid Syndrome (Phase 2): the indexed record reports TEAE = NNZ-2591 was well tolerated; most treatment-emergent adverse events were mild to moderate.
- An Open Label Trial of Growth Hormone in Children and Adolescents With Phelan-McDermid Syndrome Targeting Social Withdrawal (Phase 2): the indexed record reports Irritability baseline(Mean) = 10.31 score on a scale (Standard Deviation, 7.6); -; -.
- Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome (Phase 2): the indexed record reports TESAE(gastroenteritis) = 1 pts.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including NNZ-2591 (Phase 3; IGF-1), RB-001 (Phase 1). Company & Deal Intelligence records identify sponsor context for Neuren Pharmaceuticals Ltd. (NEU), Assistance Publique des Hôpitaux de Paris SA, Peking University First Hospital. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Natural-history-aligned endpoints that remain interpretable in small heterogeneous cohorts.
- Long-term registries for durability, immunogenicity and delayed safety signals.
- Redosing, rescue and treatment-sequencing strategies after incomplete response.
- Access models that address diagnosis, manufacturing and global delivery.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Phelan-McDermid Syndrome has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
